Ablative laser skin resurfacing with either carbon dioxide (CO 2 ) or erbium:yttrium-aluminum-garnet (Er:YAG) laser systems is a well accepted treatment for facial rejuvenation, predictably improving the appearance of photoinduced rhytides and dyschromia. 1 However, complete epidermal ablation induced by these systems results in loss of cutaneous barrier function and an extended postoperative recovery period. Untoward side effects include prolonged erythema, pigmentatry alteration, infection, and, in rare cases, fibrosis and scarring. 2-4 Furthermore, because of the high risk of scarring in nonfacial areas because of a relative paucity of pilosebaceous units in nonfacial skin, the use of ablative laser skin resurfacing is limited to facial areas.
Nonablative Systems
To address the risks associated with ablative laser skin resurfacing, nonablative laser systems were developed. Nonablative laser or light-based systems (including 1064-and 1320-nm Nd:YAG, 1450-nm diode, 1540-nm erbium glass lasers, and intense pulsed light systems) combine epidermal surface cooling with infrared or near-infrared wavelengths that create a controlled thermal injury. In studies using various nonablative devices, neocollagenesis was evident on histologic evaluation with minimal side effects, but clinical improvement was modest and often inconsistent. [5] [6] [7] [8] [9] Moreover, photoinduced dyschromia, which is often seen in conjunction with wrinkles, is not adequately addressed with completely nonablative laser systems.
FRACTIONAL PHOTOTHERMOLYSIS
Introduced by Manstein et al 10 in 2003, fractional photothermolysis was developed to overcome the aforementioned shortcomings associated with cutaneous laser resurfacing and is based on the creation of spatially precise microscopic thermal wounds with sparing of the surrounding tissue. Fractional resurfacing is performed using a 1550-nm erbium fiber laser (Fraxel; Reliant Technologies, Mountain View, CA) that targets watercontaining tissue to effect photocoagulation of narrow, sharply defined columns of skin known as microscopic thermal zones (MTZs), at depths of 200 µm to 500 µm and spaced at 200-to 300-µm intervals. Histologic evaluation of the MTZ demonstrates homogenization of dermal matrix and the formation of microscopic epidermal necrotic debris (MEND) that corresponds to the extrusion of damaged epidermal components by viable keratinocytes at the lateral margins of the MTZ. The depth of penetration of each MTZ is energy dependent and can be tailored to the characteristics of the treatment area (ie, facial vs nonfacial skin). Increases in pulse energy lead to increases in MTZ depth and width without compromising the structure or viability of interlesional tissue. 11 The MEND exfoliates several days after treatment, lending the skin a bronzed appearance. 12 The wound healing response differs from ablative techniques because the epidermal tissue that is spared between thermal zones contains viable transient amplifying cells, capable
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Fractional photothermolysis, based on creating spatially precise microscopic thermal wounds, is performed using a 1550-nm erbium fiber laser that targets water-containing tissue to effect the photocoagulation of narrow, sharply defined columns of skin known as microscopic thermal zones. According to the authors, Fraxel resurfacing has been shown to be both safe and effective for facial and nonfacial photodamage, atrophic acne scars, hypopigmented scars, and dyspigmentation. Because only a fraction of the skin is treated during a single session, a series (typically 3 to 6 treatments) of fractional resurfacing at 2-to 4-week intervals is required for the best clinical improvement. It is the authors' experience that a series of Fraxel treatments can achieve a similar clinical result for atrophic scars compared with traditional ablative laser skin resurfacing. However, the improvement seen after a series of Fraxel treatments for perioral laxity and rhytides often falls short of the impressive results that can be achieved with ablative laser skin resurfacing. (Aesthetic Surg J 2008;28:***.) of rapid reepithelialization. Furthermore, because the stratum corneum has a low water content, it remains intact immediately after treatment, thereby maintaining epidermal barrier function and reducing the risk of infection. In addition, fractional resurfacing can provide an advantage over purely nonablative laser treatments because of the gradual exfoliation of the epidermis with resultant improvement in superficial dyspigmentation.
Investigators have shown Fraxel laser resurfacing to be both safe and effective for a variety of indications, including facial and nonfacial photodamage, atrophic acne scars, hypopigmented scars, and dyspigmentation (Figures 1 through 3) . [13] [14] [15] [16] [17] [18] [19] [20] [21] Because only a fraction of the skin is treated during a single session, a series (typically 3 to 6 treatments) of fractional resurfacing at 2-to 4-week intervals is required for the best clinical improvement.
Side Effects and Complications
Side effects of fractional resurfacing are typically mild and transient, including erythema and periocular edema, and a slight darkening of the skin (bronzing) as the MEND desquamate. The overall complication rate is significantly lower with fractional skin resurfacing than that reported after ablative laser skin resurfacing. [1] [2] [3] [4] A retrospective evaluation of 961 successive 1550-nm Fraxel laser treatments in patients with various skin phototypes (Fitzpatrick types I through V) was conducted in a single clinical center. 22 There were 73 reported complications in 961 treatments (7.6%). The most frequent complications were acneiform eruptions (n = 18; 1.87%), herpes simplex virus (HSV) outbreaks (n = 17; 1.77%), and erosions (n = 13; 1.35%). Less frequent side effects included postinflammatory hyperpigmentation (n = 7; 0.73%), prolonged erythema (n = 8; 0.83%), prolonged edema (n = 6; 0.62%), and dermatitis (n = 2; 0.21%). To reduce the risk of HSV outbreak, oral HSV prophylaxis is recommended for those patients with a strong history of herpes labialis. Acne-prone patients were more likely to experience posttreatment acne, presumably because of the disruption of follicular units during treatment and reep- ithelialization. The use of oral antibiotics (eg, doxycycline, 20 mg daily) during subsequent treatments prevented future outbreaks in these patients.
To date, permanent pigmentary alteration and scarring have not been reported. However, when an aggressive treatment protocol is used, placing a high density of MTZ, the risk of visible epidermal ablation is increased along with the side effects and complications associated with ablative laser procedures.
CONCLUSIONS
As demand grows for minimally invasive treatments to address the signs of aging and photodamage, clinicians will be challenged to develop procedures that combine reliable clinical results with minimal posttreatment recovery. Based on its demonstrated clinical efficacy and excellent side effect profile in a wide range of skin types, fractional photothermolysis is considered a first-line treatment for cutaneous resurfacing. To date, there are no published reports evaluating the clinical efficacy of traditional ablative laser skin resurfacing compared with nonablative fractional resurfacing. It is the authors' experience that a series of Fraxel treatments can achieve a similar clinical result for atrophic scars compared with traditional ablative laser skin resurfacing. However, the improvement seen after a series of Fraxel treatments for perioral laxity and rhytides often falls short of the impressive results that can be achieved with ablative laser skin resurfacing.
Over the next several years, variations on the theme of fractional photothermolysis, including ablative fractional photothermolysis with highly advanced CO 2 and Er:YAG laser systems, will continue to advance cutaneous laser resurfacing toward the ultimate goal of maximum clinical improvement coupled with minimal recovery and side effects. AQ5: For Figures 1, 2, and 3 , please provide the ages of the patients. Thank you.
